Predictive biomarker of Neuromyelitis Optica spectrum disorders relapse

Applications: Disease monitoring, treatment response, autoimmune encephalitis

In patients with NMOSD, disability accumulates primarily through relapses. Researchers at Oxford have identified AQP4-IgM and AQP4-IgG subclasses as autoantibodies linked to an increased risk of relapse. This can be used as a biomarker for determining treatment or recruiting for clinical trials.

Features	Benefits
Detects Aquaporin-4 (AQP4)-IgM or specific AQP4-IgG subclasses indicative of relapse	Only biomarker available for identification of relapse in patients with NMOSD
AQP4-IgM and AQP4-IgG subclasses had a strong odds ratio for an association with relapses (~6), including a high negative predictive value (~9)	Accurate identification of those at risk of relapse for use by: Routine clinical care Healthcare providers to decide on provision of expensive/toxic therapies Clinical trials to help define endpoints, with relapses often the primary endpoint for NMOSD
Serum-based test	Minimally invasive Easily obtained and stored for analysis
Assay detects treatment associated reductions in antibodies that cause relapses	Can be used as a biomarker for treatment response, or in clinical trials to evaluate efficacy of therapeutic

Patented & Available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Predictive biomarker of Neuromyelitis Optica spectrum disorders relapse

Ready to get in touch?